Latest Urate oxidase Stories
New review outlines the data supporting the relationship between urate-lowering efficacy and the risk for infusion reactions with Krystexxa® (pegloticase), the only FDA-approved treatment for chronic
-- 3SBio's pegsiticase has shown a promising efficacy and safety profile in early clinical trials and Selecta and 3SBio plan to advance clinical studies of pegsiticase-based treatments for refractory
Acquisition is highlighted by KRYSTEXXA® (pegloticase), the only product approved for the treatment of refractory chronic gout GLENDALE, Wis., Jan.
- The act of sweetening by admixture of some saccharine substance.